Liver Health Diagnostics to Star at Phoenix Conference
Experts will gather in Phoenix on October 13 to discuss managing metabolic health and liver disease.
Updated on Oct. 8, 2026 in Diabetes
Live Poll
Should your employer prioritize funding for expensive specialty drugs or early disease screening programs?
The SIIA National Conference 2026 will feature a panel on October 13, 2026, focused on metabolic health and liver disease management strategies. The session highlights diagnostic tools for patients with conditions like obesity and type 2 diabetes.
Why it matters
Metabolic dysfunction-associated steatotic liver disease (MASLD) is frequently asymptomatic, making it difficult to detect with standard testing. Improved identification of fibrosis is essential for clinical management in populations with high metabolic risk.
FibroScan technology is supported by over 5,600 peer-reviewed publications and 220 international clinical guidelines. Research indicates that among patients with MASH, 82% have obesity, 44% have type 2 diabetes, and 71% have metabolic syndrome.
The players
Shawn McGinnis
Director of Health Systems and Employer Markets at Echosens who focuses on integrating liver diagnostic technologies into clinical practice.
Echosens
A medical technology company based in Westborough, Massachusetts, that develops the FibroScan device for non-invasive liver assessment.
The details
FibroScan serves as a non-invasive tool for measuring liver stiffness and fat content, offering a rapid assessment compared to more invasive diagnostic procedures. The technology integrates into existing clinical workflows through provider training and onboarding to assist in identifying liver disease early in at-risk populations. By providing objective data on liver health, it aids clinicians in monitoring patients who have metabolic comorbidities.
Timeline
The panel at the SIIA National Conference 2026 occurs in Phoenix on October 13, 2026.
Health Landscape
The session highlights the broader shift toward integrating non-invasive diagnostic tools into standard metabolic health care. It reflects the ongoing clinical effort to improve early detection of MASLD in patient populations with high rates of obesity and diabetes.
Patients with metabolic conditions like type 2 diabetes or obesity should discuss liver health screening options with their primary care physician. Understanding your risk for asymptomatic liver disease is a vital step in maintaining long-term metabolic health.
The takeaway
Early identification of liver disease is a critical component of metabolic health management for those with diabetes and obesity. Ask your physician about appropriate non-invasive screenings if you have complex metabolic risk factors.
Further reading
For more on managing metabolic health, visit the Diabetes section.
More information
Learn more about this diagnostic technology at the Echosens corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Should your employer prioritize funding for expensive specialty drugs or early disease screening programs?
